Pharmaceutical - Diabetes, Research

Filter

Current filters:

DiabetesResearch

Popular Filters

1 to 25 of 137 results

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

12-12-2014

The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society UK announced new funding…

CialisDiabetesEli LillyliraglutideMen's HealthNeurologicalNovo NordiskPharmaceuticalResearchTadalafilVictoza

Sanofi showcases next wave of medicines and vaccines

20-11-2014

French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

International Diabetes Federation releases focus on Middle East

14-11-2014

The International Diabetes Federation has published its sixth Diabetes Atlas with a particular focus…

DiabetesMiddle EastPharmaceuticalResearchRest of the World

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

Physicians in South Korea and Taiwan expect good uptake of SGLT-2 inhibitors

Physicians in South Korea and Taiwan expect good uptake of SGLT-2 inhibitors

20-10-2014

Prescribers are enthusiastic about the emergence of SGLT2-2 inhibitors for type 2 diabetes, but payers…

AbasriaAsia-PacificDiabetesLantusPharmaceuticalResearch

Age is a factor when looking at diabetes management, Sanofi survey finds

Age is a factor when looking at diabetes management, Sanofi survey finds

15-10-2014

The US subsidiary of French pharma major Sanofi has announced the findings of a new survey that reveals…

DiabetesPharmaceuticalResearchSanofiUSA

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

08-10-2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential…

AdociaBioChaperoneDiabetesFIAspGlobalMarkets & MarketingNovo NordiskPharmaceuticalResearch

Attack type 2 diabetes from a new direction, says new research

Attack type 2 diabetes from a new direction, says new research

06-10-2014

Type 2 diabetes affects an estimated 28 million Americans, according to the American Diabetes Association,…

DiabetesEndocrine systemPharmaceuticalResearchUSAVictor Shengkan Jin

Intarcia’s Phase III diabetes data shows sustained blood sugar control

Intarcia’s Phase III diabetes data shows sustained blood sugar control

02-10-2014

USA-based Intarcia Therapeutics has announced successful top-line results from two of its four Phase…

DiabetesExenatide InjectionIntarcia TherapeuticsPharmaceuticalResearchUSA

Long-acting insulin is safer, more effective for patients with type 1 diabetes

Long-acting insulin is safer, more effective for patients with type 1 diabetes

01-10-2014

Long-acting insulin is safer and more effective than intermediate-acting insulin for patients with type…

CanadaDiabetesInsulin DetemirInsulin Glargine [rDNA origin] InjectionPharmaceuticalResearch

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

19-09-2014

The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent…

DenmarkDiabetesEuropeMexicoNovo NordiskPharmaceuticalResearchRyzodegTresibaXultophy

First Ph III data in Japanese patients for Merck’s omarigliptin for type 2 diabetes

18-09-2014

US pharma giant Merck & Co has announced the presentation of the first data from the Phase III clinical…

DiabetesJapanMerck & CoomarigliptinPharmaceuticalRegulationResearch

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

Empagliflozin/linagliptin combo shows sustained reduction in blood glucose in Ph III

16-09-2014

Family-owned German pharma major Boehringer Ingelheim and US partner Eli Lilly have presented results…

Boehringer IngelheimDiabetesEli LillyempagliflozinlinagliptinPharmaceuticalResearch

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

04-09-2014

US pharma major Eli Lilly has released additional clinical data showing superiority for its diabetes…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

Positive new Ph III data with Novo Nordisk’s Xultophy

Positive new Ph III data with Novo Nordisk’s Xultophy

11-08-2014

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchXultophy

A$35 million to advance Australian type 1 juvenile diabetes research

A$35 million to advance Australian type 1 juvenile diabetes research

10-07-2014

Australia’s Minister for Education, Christopher Pyne, and Minister for Health, Peter Dutton, have today…

AustraliaDiabetesFinancialPharmaceuticalResearch

ImmuPharma extends research capabilities via French connection

27-06-2014

UK-based drug discovery firm ImmuPharma has extended its research capabilities by setting up its own…

DiabetesImmuPharmaPharmaceuticalResearchUrelix

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

1 to 25 of 137 results

Back to top